跳至主要内容
临床试验/EUCTR2013-004323-37-ES
EUCTR2013-004323-37-ES进行中(未招募)不适用

Single nucleotide polymorphism association with response and toxic effects in patients with Ph+ CP-CML treated with bosutinib after relapse or intolerance to previous treatment. - BOSTRO

Fundación PETHEMA para el tratamiento de la leucemia y el linfoma0 个研究点目标入组 50 人开始时间: 2015年2月9日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Signed and dated informed consent form.
  • 2.Patients with chronic phase of Ph+ CML who showed failure to previous TKI treatment. Failure is defined as BCR-ABL >10% by qRT-PCR (IS) at 3 months of treatment initiation.
  • 3.ECOG Performance Status of 0 or 1.
  • 4.Recovered to Grade 0-1, or to baseline, from any toxicities of prior treatment, other than alopecia
  • 5.Able to take daily oral capsules
  • 6.Adequate bone marrow function: a. Absolute neutrophil count > 1000/mm3 (>1000 x109/L) b. Platelets ? 100,000/mm3 (>100 x109/L) absent any platelet transfusions during the preceding 14 days.
  • 7.Adequate hepatic, and renal function:
  • oAST/ALT ? 2.5 × upper limit of normal (ULN) or ? 5 × ULN if attributable to liver involvement of leukemia
  • oTotal bilirubin ? 1.5 × ULN
  • oCreatinine ? 1.5 × ULN
  • 8.Age > 18 years
  • 9.Willingness of male and female subjects, who are not surgically sterile or postmenopausal, to use reliable methods of birth control (oral contraceptives, intrauterine devices, or barrier methods used with a spermicide) for the duration of the study and for 30 days after the last dose of Bosutinib.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 50
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 50

排除标准

  • 1.Subjects with Philadelphia chromosome and bcr-abl negative CML.
  • 2. Overt leptomeningeal leukemia. Subjects must be free of CNS involvement for a minimum of 2 months. Subjects with symptoms of CNS involvement must have a diagnostic lumbar puncture prior to study enrollment.
  • 3.Subjects with extramedullary disease only.
  • 4.Prior stem cell transplantation.
  • 5.Major surgery within 14 days or radiotherapy within 7 days before the first dose of Bosutinib (recovery from any previous surgery should be complete before day 1)
  • 6.A history of a clinically significant ventricular arrhythmia, congenital or acquired prolonged QT interval, a baseline QTcF > 0.47 sec (average of triplicate readings) or unexplained syncope, uncontrolled or symptomatic congestive heart failure (CHF) within 3 months, or myocardial infarction (MI) within 6 months.
  • 7.Concomitant use of or need for medications known to prolong the QT interval
  • 8.Uncorrected hypomagnesemia or hypokalemia due to potential effects on the QT interval
  • 9.Recent (within 30 days of study entry) or ongoing clinically significant gastrointestinal disorder (e.g., malabsorption, short bowel syndrome, bleeding, or grade >1 diarrhea, nausea or emesis lasting more than 2 days, despite adequate medical therapy)
  • 10.Pregnant or breastfeeding women
  • 11.Evidence of serious active infection, or significant medical or psychiatric illness
  • 12.Known seropositivity to HIV, or current acute or chronic Hepatitis B or Hepatitis C (antigen positive), cirrhosis, hypokalemia (any grade), or clinically significant abnormal laboratory finding that would, in the investigator?s judgment, make the subject inappropriate for this study.

研究者

发起方
Fundación PETHEMA para el tratamiento de la leucemia y el linfoma

相似试验